dna intercalators and using them as anticancer drugs

Authors

masoud karimi goftar

nasrollah moradi kor

zahra moradi kor

abstract

many anticancer drugs in clinical use interact with dna through intercalation, which is process that starts with the transfer of the intercalating molecule from an aqueous environment to the hydrophobic space between two adjacent dna base pairs. in general, intercalatig agents are two types: monofunctional and bifunctional. monofunctional intercalators contain one intercalating unit and bifunctional intercalators (bis-intercalators) contain two intercalating units, normally cationic, separated by a spacer chain that must be long   enough to allow double intercalation taking into account the neighbour exclusion principle.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

DNA Intercalators and Using Them as Anticancer Drugs

Many anticancer drugs in clinical use interact with DNA through intercalation, which is process that starts with the transfer of the intercalating molecule from an aqueous environment to the hydrophobic space between two adjacent DNA base pairs. In general, intercalatig agents are two types: monofunctional and bifunctional. Monofunctional intercalators contain one intercalating unit and Bifunct...

full text

DNA Intercalators and Using Them as Anticancer Drugs

Many anticancer drugs in clinical use interact with DNA through intercalation, which is process that starts with the transfer of the intercalating molecule from an aqueous environment to the hydrophobic space between two adjacent DNA base pairs. In general, intercalatig agents are two types: monofunctional and bifunctional. Monofunctional intercalators contain one intercalating unit and Bifunct...

full text

Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances.

Over the past forty years, anthracyclines and ellipticines have attracted attention as promising cytostatics. In this review, we focus on their mechanisms of cytoxicity, DNA-damaging effects and adverse side-effects. We also summarize ways to enhance the therapeutic effects of these drugs together with a decrease in their adverse effects. Current drug design strategies are focused on drug bioav...

full text

Transition Metal Intercalators as Anticancer Agents—Recent Advances

The diverse anticancer utility of cisplatin has stimulated significant interest in the development of additional platinum-based therapies, resulting in several analogues receiving clinical approval worldwide. However, due to structural and mechanistic similarities, the effectiveness of platinum-based therapies is countered by severe side-effects, narrow spectrum of activity and the development ...

full text

Polyamine analogues as anticancer drugs.

Just over 30 years ago, the late Diane Russell published the first in a series of papers linking polyamines and cancer. These early studies led to a flurry of research activity in the polyamine field that continues to this day attempting to identify a role for the polyamines in cancer development, treatment and/or prevention. The recognition that polyamines are critical for the growth of cancer...

full text

My Resources

Save resource for easier access later


Journal title:
international journal of advanced biological and biomedical research

Publisher: casrp publishing company

ISSN 2383-2762

volume 2

issue 3 2014

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023